4 recruiting, 2 not yet recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Daraxonrasib: new trials by email Literature Review of Daraxonrasib trials Research Report on Daraxonrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daraxonrasib in Resectable PDAC Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Not yet recruiting | Dana-Farber Cancer Institute | 30 | 2027-04-13 | 2026-10-27 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer SNV1521, daraxonrasib - Pancreatic Cancer, Pancreatic Acinar Carcinoma | Phase 1 | Recruiting | ParVation Therapeutics, Inc. | 40 | 2026-09-01 | 2026-10-27 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-11-04 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
Pancreatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Lung Neoplasms (2) · Appendiceal Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Intestinal Neoplasms (1) · Lung Diseases (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Revolution Medicines, Inc. (3) · Children's Oncology Group (1) · Dana-Farber Cancer Institute (1) · ParVation Therapeutics, Inc. (1)
United States (5) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · Spain (1)
Amit J Sabnis (1) · Brandon Huffman, MD (1) · Revolution Medicines, Inc. (1)
UM1CA228823 (1)